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Abstract 
Background: Roux-en-Y gastric bypass (RYGB) reduces body weight and cardiovascular 
mortality in morbidly obese patients. Glucagon-like peptide-1 (GLP-1) seems to mediate the 
metabolic benefits of RYGB partly in a weight loss-independent manner. The present study 
investigated in rats and patients whether obesity-induced endothelial and HDL dysfunction 
are rapidly improved after RYGB via a GLP-1-dependent mechanism.  
Methods and Results: Eight days after RYGB in diet-induced obese rats, higher plasma 
levels of bile acids and GLP-1 were associated with improved endothelium-dependent 
relaxation compared to sham-operated controls fed ad libitum and sham-operated rats that 
were weight-matched to those undergoing RYGB. Compared to sham-operated rats, RYGB 
improved nitric oxide (NO) bioavailability due to higher endothelial Akt/NO synthase 
activation, reduced JNK-phosphorylation and decreased oxidative stress. The protective 
effects of RYGB were prevented by the GLP-1 receptor antagonist exendin9-39 (10ug/kg/h). 
Further, in patients and rats RYGB rapidly reversed HDL dysfunction and restored the 
endothelium-protective properties of the lipoprotein, including eNOS activation, NO 
production as well as anti-inflammatory, anti-apoptotic and anti-oxidant effects. Finally, 
RYGB restored HDL-mediated cholesterol efflux capacity. To demonstrate the role of 
increased GLP-1 signaling, sham-operated control rats were treated for eight days with the 
GLP-1 analog liraglutide (0.2 mg/kg twice daily), which restored NO bioavailability, 
improved endothelium-dependent relaxations and HDL endothelium-protective properties, 
mimicking the effects of RYGB.  
Conclusions: RYGB rapidly reverses obesity-induced endothelial dysfunction and restores 
the endothelium-protective properties of HDL via a GLP-1-mediated mechanism. The present 
translational findings in rats and patients unmask novel, weight-independent mechanisms of 
cardiovascular protection in morbid obesity.  
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Introduction 
 
Obesity is a worldwide health problem due to the associated increased morbidity and 
cardiovascular mortality1. Accompanying metabolic disorders such as insulin resistance, type 
2 diabetes mellitus (T2DM) and risk factors such as dyslipidemia increase the disease risk 
linked to obesity. In particular, obesity induces endothelial dysfunction which precedes 
atherosclerosis, but also contributes to insulin resistance in tissues involved in glucose and 
lipid metabolism2, 3. Reduced nitric oxide (NO) bioavailability seems to be the primary defect 
that links obesity, insulin resistance and endothelial dysfunction2, 3. 
Furthermore, obesity and insulin resistance result in pro-atherogenic dyslipidemia4 
characterized by high low density lipoproteins (LDL) and triglyceride (TG) and low high-
density lipoproteins (HDL) cholesterol plasma levels1, 5. Abnormal HDL remodeling and 
maturation have been reported in obese subjects with a HDL profile similar to that of subjects 
with established cardiovascular disease5. In addition, pathological situations associated with 
obesity, in particular T2DM6 and coronary artery disease7, impair the physiological protective 
properties of HDL, which preserves endothelial NO bioavailability and promotes vascular 
health8. Once dysfunctional, HDL may contribute to endothelial dysfunction8. Thus, assessing 
the properties of HDL is more informative than measuring its plasma levels alone8.  
Roux-en-Y gastric bypass surgery (RYGB) induces sustained weight loss in contrast to the 
limited success of pharmacological or behavioral interventions9, 10. Reduction in global and 
cardiovascular mortality 9, 11 and obesity-related co-morbidities1, 10, 12, 13 have been reported 
after RYGB1, 11. The mechanisms underlying these beneficial effects are multiple1, 11. 
Amelioration of insulin resistance14 or even resolution of T2DM occurs within days after 
RYGB, before any substantial weight loss. These findings suggested that glycemic control is 
restored by mechanisms15, 16 related to the unique anatomical gut re-arrangement and the 
altered flow of nutrients after RYGB10, rather than simply as the consequence of weight loss15, 
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17. After RYGB, the modified entero-hepatic circulation of bile acids increases their 
intraluminal and systemic concentrations. Thus, elevated levels of these acids and undigested 
chyme may modify the release of gastrointestinal hormones17. In particular, plasma levels of 
the gut hormone glucagon-like peptide-1 (GLP-1) increase rapidly after RYGB, but not after 
dietary restriction, despite a similar weight loss15, 16, 18. These observations raised the 
hypothesis that changes in GLP-1 levels mediate the rapid and surgery-specific metabolic 
improvement achieved after RYGB18, 19. Drugs targeting the GLP-1 system are used in 
clinical practice as anti-diabetic agents with potential weight-lowering effects20. Beyond its 
metabolic actions, GLP-1 exhibits multiple beneficial properties, in particular anti-oxidant 
and endothelium-protective effects19, 21.  
Therefore, the present study was designed to evaluate whether RYGB causes a rapid 
improvement in endothelial function and restores the protective properties of HDL. Moreover, 
the experiments examined whether increased GLP-1 levels mediate the rapid metabolic and 
cardiovascular improvements associated with RYGB and if results of the procedure in obese 
rat can be translated to obese patients. 
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Materials and Methods 
An expanded description of methods is available in supplemental online materials (SOM).  
 
Animals and organ chamber experiments 
Male Wistar rats were fed a high fat high cholesterol diet containing 60% kcal fat and 1.25% 
cholesterol for seven weeks prior and after surgery to achieve diet-induced obesity. Two main 
experiments were performed (SOM Fig. 1) with: a.) RYGB22, sham-operated rats either fed 
ad libitum (controls) or weight-matched to RYGB and followed up for eight days. b.) Rats 
randomized to two treatment groups for the eight days of follow-up: controls treated with 
either vehicle or liraglutide (0.2 mg/kg twice daily) and RYGB treated with either vehicle or 
exendin9-39 (10ug/kg/h). In addition, some rats were followed-up for one month after surgery. 
All animal experiments were approved by the Zurich Cantonal Veterinary Office. Cumulative 
concentration-relaxation curves in response to insulin and GLP-1 were obtained in rings of 
thoracic aorta as described23. 
 
Endothelium-protective properties of HDL 
HDL was isolated from rat and patient serum by sequential density ultracentrifugation6, 7. 
HDL-stimulated NO production by cultured human aortic endothelial cells (HAEC) was 
tested in vitro using the fluorescent probe 4,5-diaminofluorescein (DAF-2)7. HDL anti-
apoptotic properties were assessed in HAEC24. Arylesterase activity of HDL-associated 
paraoxonase-1 (PON-1) was measured by UV spectrophotometry7. Endothelial protein 
expression of vascular cell adhesion molecule 1 (VCAM-1) was determined in TNF-α 
stimulated (100pg/ml) HAEC treated with HDL7. NADPH oxidase activity was measured 
using a commercial assay kit. 
 
6 
CIRCULATIONAHA/2014/011791R1 
Patient population  
The surgery group consisted of 29 patients undergoing primary laparoscopic proximal 
RYGB25. The BMI-matched group consisted of 29 obese patients matched for BMI, body 
weight, age and gender to the RYGB group at week 12 after surgery. Moreover, 28 normal-
weight volunteers matched for age and sex were enrolled. The Local Research and Ethics 
committee approved the study. All patients gave written consent 
 
Statistical Analysis 
Continuous variables with no/mild skew were presented as mean ± SEM; skewed measures as 
median and inter-quartile ranges (IQR). Discrete variables were summarized as frequencies 
and percentages. The distribution of the data was analyzed with one-sample Shapiro-Wilk 
test. Logarithmic transformation was performed to achieve normal distribution for skewed 
variables. Categorical variables were compared with χ2 test or Fisher exact test, as 
appropriate. Continuous data were compared by use of the 2-tailed paired or unpaired t test 
(for normally distributed data sets) or the Mann-Whitney U or Wilcoxon signed-rank test (for 
skewed variables). We used a two-way ANOVA with repeated measures to compare repeated 
measurements on the same animals. For studying the complete outcome of each variable over 
time, we applied the linear mixed model using unstructured covariance matrix for quantitative 
variables. All tests were two-sided and statistical significance was accepted if the null 
hypothesis could be rejected at p<0.05. The authors had full access to and take full 
responsibility for the integrity of the data. All authors have read and agree to the manuscript 
as written. 
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Results 
 
GLP-1 and bile acids plasma levels increase rapidly after RYGB 
Fasting circulating GLP-1 levels were significantly higher in RYGB than in sham-operated 
rats (Fig. 1A-B and SOM Fig. 2A). RYGB receiving exendin9-39 had GLP-1 levels similar to 
RYGB (Fig. 1B). Fasting plasma bile acid levels were increased after RYGB in all 
experiments (Fig 1C-D and SOM Fig. 2B) and were not affected significantly by either 
liraglutide or exendin9-39.  
 
The rapid improvement of vascular function after RYGB is weight-independent 
Physiologically, insulin and GLP-1 induce NO-mediated endothelium-dependent 
relaxations19, 26, whereas decreased NO bioavailability in obesity impairs endothelial 
function2, 3, 26 . Therefore, the impact of RYGB on relaxations in response to increasing 
concentrations of both hormones was tested. Pre-incubation of the aortic rings with the NO 
synthase (NOS)-inhibitor Nω-nitro-L-arginine methyl ester (L-NAME) abolished 
endothelium-dependent relaxations in response to both hormones, indicating an NO-
dependent mechanism (data not shown). The relaxing effect of GLP-1 was inhibited by 
incubation of the aortic rings with the specific GLP-1 receptor antagonist, exendin9-39 (10-5 
mol/L) (SOM Fig. 4A).  
The responses to insulin and GLP-1, improved significantly eight days after RYGB, but not 
in weight-matched rats (Fig. 2A-B; SOM Fig.3 A-B). Acetylcholine-induced relaxations were 
also restored rapidly after RYGB (SOM Fig. 4B). One month after surgery, responses to both 
insulin and GLP-1 remained impaired in controls and weight-matched rats, but the 
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acetylcholine-induced relaxation improved similarly in aortae of weight-matched and RYGB 
rats (SOM Fig. 3 E-F and SOM Fig. 4 D-F).  
 
RYGB improves endothelial function by a GLP-1 receptor-dependent mechanism 
To investigate the role of GLP-1 in the improved relaxation after RYGB, the GLP-1 receptor 
antagonist, exendin9-39 or the GLP-1 analog, liraglutide, were administered for eight days 
after RYGB (RYGB-exendin9-39) or to control (controls-liraglutide) rats, respectively. The 
relaxations improved in response to insulin and GLP-1 in controls-liraglutide compared to 
controls, thus mimicking RYGB’s effects (Fig. 2 C-D). Instead, RYGB-exendin9-39 rats had 
blunted relaxations to insulin and GLP-1 compared to RYGB, i.e. they were not significantly 
different from controls (Fig. 2 C-D and SOM Fig.3 C-D). Relaxations to acetylcholine in 
RYGB-exendin9-39 were similar to those of RYGB rats (SOM Fig 4G). Relaxations to the 
endothelium-independent vasodilator sodium nitroprusside were similar among all 
experimental groups (SOM Fig. 4 C, H).  
 
Vascular GLP-1 signaling is increased in RYGB rats independently of weight loss 
Consistent with the improved relaxations to GLP-1 seen after RYGB, the aortic GLP-1 
receptor expression was increased in RYGB compared to sham-operated rats eight days after 
surgery (Fig 3A).  
Insulin and GLP-1-signaling in endothelial cells results in phosphorylation of protein kinase 
Akt at serine 473 (pSer473-Akt) followed by phosphorylation of eNOS on Ser1177 
(pSer1177eNOS), a well-known eNOS-activating pathway 24, 27. The phosphorylation level of 
pSer473-Akt was significantly higher after RYGB compared to control rats (Fig 3B, Fig 4A) 
9 
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and in controls-liraglutide compared to their controls, while it was reduced in RYGB-exendin9-39 
(Fig 4 A).  
Obesity increases c-Jun amino terminal kinases (JNK) activity, which in turn impairs insulin 
and GLP-1 signaling28, 29. JNK phosphorylation (p-JNK) was reduced significantly after 
RYGB compared to sham-operated groups (Fig 3C). Exendin9-39 prevented the reduction in 
JNK phosphorylation after RYGB. Controls-liraglutide rats had slightly decreased JNK 
activation compared to controls, but the degree of inhibition was lower than after RYGB (Fig. 
4 B). 
NO bioavailability was preserved after RYGB compared to sham-operated groups as 
reflected by an increased pSer1177eNOS and decreased inhibitory Thr495 phosphorylation of 
eNOS30, a higher eNOS dimer-to-monomer ratio and an augmented aortic NO production (Fig 
3 D-G). Moreover, in RYGB we observed a lower eNOS-glutathionylation, which impairs the 
enzyme function31, compared to weight-matched rats (SOM Fig.5A). Despite an only slightly 
higher pSer1177eNOS, pThr495 was reduced, and dimerization of eNOS and NO production 
were increased in controls-liraglutide aortae to levels comparable to RYGB; by contrast, eNOS 
activation and NO production were reduced in RYGB-exendin9-39. However, eNOS-
glutathionylation was not affected by GLP-1 modulation (Fig 4 C-F, SOM Fig.5 B). 
 
Decreased oxidative stress contributes to the preserved NO bioavailability after RYGB 
High oxidative stress in obesity leads to NO inactivation by superoxide anions (O2-) and 
may impair endothelial NO availability. Concurrent with this notion, the addition of the free 
radical scavenger Polyethylene Glycol–Superoxide Dismutase (PEG-SOD) significantly 
improved relaxations in response to insulin and GLP-1 in both sham-operated rats. In RYGB 
and in controls-liraglutide PEG-SOD did not modify relaxations, suggesting that the level of 
oxidative stress was reduced by the surgery and liraglutide. Instead PEG-SOD was beneficial 
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in RYGB-exendin9-39 confirming the important vascular antioxidant effect of GLP-1 and analogs 
(SOM Fig. 4 I-N). In addition, O2- concentration and NADPH oxidase activity, which is a 
major oxidant enzyme system producing O2- in the vasculature6, were decreased in aortae of 
rats after RYGB compared to controls and weight-matched rats (Fig 5 A-C). In controls, 
treatment with liraglutide reduced aortic O2- concentration (Fig5A-B) and also, though to a 
lesser extent, aortic NADPH oxidase activity, mimicking RYGB; instead, exendin9-39 
treatment after RYGB did not counteract these antioxidant effects (Fig.5 C).  
 
Endothelium-protective properties of HDL improve rapidly after RYGB  
Endothelium-protective properties of HDL and the role of the increased circulating GLP-1 
levels as mediators of the observed changes were assessed. In parallel to the rat studies, 
similar experiments were performed with HDL obtained from patients before, 14 days and 12 
weeks after RYGB and from the BMI-matched group. See SOM Tables 1-2 for patient 
characteristics. 
 
HDL-stimulated endothelial NO production increases rapidly after RYGB 
HDL isolated from RYGB rats induced higher endothelial-NO production in HAEC than 
HDL from controls (Fig 6 A). Furthermore, HDL from controls-liraglutide rats stimulated 
endothelial NO production in a similar fashion as HDL isolated after RYGB. This effect was 
independent of GLP-1 receptor activation because it was preserved in RYGB rats treated with 
exendin9-39 (Fig. 6 D).  
The capacity of HDL isolated from patients to stimulate NO production increased already at 
day 14 and was normalized 12 weeks after RYGB compared to the pre-operative period (Fig 
7A). The NO production stimulated by HDL isolated from the BMI-matched group was 
reduced compared to patients 12 weeks after RYGB. Accordingly, HAEC stimulated with 
HDL isolated from patients at day 14 and week 12 after RYGB exhibited improved eNOS 
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dimerization relative to their pre-operative HDL; eNOS dimerization was impaired in the 
BMI-matched group compared to 12W (p< 0.055) (Fig 7B). 
 
HDL reduces endothelial cell apoptosis rapidly after RYGB 
Compared to controls, HDL isolated after RYGB markedly reduced endothelial apoptosis 
induced by serum and growth factors deprivation (Fig. 6B). HDL from controls-liraglutide 
reduced endothelial apoptosis to a similar degree as after RYGB, but again treatment with 
exendin9-39 after RYGB did not influence this property of HDL (Fig. 6E). 
In patients, the capacity of HDL to inhibit endothelial apoptosis, which was impaired pre-
operatively, was restored after surgery and resembled that of healthy subjects. The anti-
apoptotic capacity of HDL was similar between patients 12 weeks after RYGB and their 
BMI-matched group (Fig. 7C). 
 
Anti-Inflammatory properties of HDL improve after RYGB  
HDL isolated after RYGB reduced TNFα–stimulated endothelial VCAM-1 expression 
significantly more than HDL from controls (Fig. 6C). HDL from controls-liraglutide rats was 
similarly effective as HDL isolated after RYGB, whereas treatment of RYGB rats with 
exendin9-39 had no effect. Hence, the increase in anti-inflammatory properties of HDL 
following RYGB is mimicked by the GLP-1 analogue, but does not involve the activation of 
the known GLP-1 receptor (Fig. 6F). Endothelial VCAM-1 expression was reduced by HDL 
from patients 12 weeks after RYGB, but not by HDL from BMI-matched subjects (Fig 7D). 
 
PON-1 activity increases rapidly after RYGB 
PON-1 activity was increased after RYGB compared to controls. The improvement of PON-
1 activity was surgery-specific, but independent of GLP-1 levels or signaling, because 
treatment with liraglutide or exendin9-39 did not modify it compared to the respective control 
12 
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groups (SOM Fig. 6 A, C). In patients, PON-1 activity improved progressively after RYGB, 
instead it was impaired in the BMI-matched group (Fig 7 E). 
 
RYGB improves the capacity of HDL to stimulate macrophage cholesterol efflux 
HDL after RYGB increased cholesterol efflux from J774 macrophages compared to HDL 
from sham-operated rats. Instead, HDL from controls-liraglutide or RYGB-exendin9-39 did not 
change this parameter compared to HDL from the respective controls, suggesting that the 
RYGB-induced effect is independent of changes in GLP-1 levels or signaling (SOM Fig. 6B, 
D). In patients 12 weeks post-RYGB, HDL improved the cholesterol efflux capacity, in 
contrast to HDL from the BMI-matched group (Fig 7F). 
 
RYGB rapidly restores the endothelial anti-oxidant effects of HDL  
In HAEC, stimulation with HDL isolated after RYGB or controls-liraglutide reduced NADPH 
oxidase activity compared to HDL from sham-operated animals; exendin9-39 treatment after 
RYGB did not alter HDL anti-oxidant effects (Fig5D). Endothelial NADPH oxidase activity 
was reduced by HDL from patients 12 weeks post-RYGB, but not by HDL from the BMI-
matched group (Fig.5E). 
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Discussion 
 
RYGB induces stable weight loss, improves obesity-associated co-morbidities and reduces 
cardiovascular mortality1, 11. Here we show that the beneficial metabolic and cardiovascular 
effects of RYGB likely result from changes in intestinal physiology rather than from weight 
loss alone. In particular, the gut hormone GLP-1, which increases rapidly after RYGB and 
restores glycemic homeostasis, may also contribute to the cardiovascular protection after 
surgery19, 32. Indeed, we found in the present study that: (1) in a rat model of RYGB, higher 
plasma levels of GLP-1 and bile acids were associated with increased aortic NO 
bioavailability, improved endothelium-dependent relaxation and normalized endothelium-
protective properties of HDL; (2) GLP-1-dependent signaling was selectively activated in rat 
aortae after RYGB and was independent of weight loss; (3) treatment of control rats with the 
GLP-1 analog liraglutide for eight days improved both endothelial and HDL function, thus 
mimicking the effects of RYGB; and (4) in morbidly obese patients, increased plasma levels 
of GLP-1 and bile acids after RYGB were associated with a rapid improvement in 
endothelium-protective properties of HDL. The major results and proposed underlying 
mechanisms are summarized in Figure 8 and SOM Table 3. 
 
Improved endothelium-dependent relaxations after RYGB involves a GLP-1-dependent 
mechanism 
 
Beyond widespread metabolic actions, GLP-1 and its analogues affect the cardiovascular 
system33 and in particular endothelial cells19, 32, but also lipid metabolism32, 34, 35. GLP-1 
exerts potent anti-oxidant effects36, and possesses anti-apoptotic and anti-inflammatory 
properties in endothelial cells24, 37. The endothelial effects of GLP-1 are NO-mediated38 and 
can be either dependent or independent of the activation of the known GLP-1 receptor33. 
14 
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Physiologically, GLP-1 promotes endothelial health indirectly by triggering insulin 
production38 and by activating its own endothelial signaling pathways32, 34, 35.  
The present findings demonstrate that increased plasma levels of GLP-1 after RYGB, 
activate GLP-1 receptor-dependent intracellular signaling and induce a rapid restoration of 
endothelium-dependent relaxations. These beneficial effects were weight-independent, 
because they were absent in rats which had a weight loss matched to RYGB. One month after 
surgery, relaxations to insulin and GLP-1 remained impaired in weight-matched compared to 
RYGB rats; this points out that weight loss achieved by food restriction is not sufficient to 
induce all the beneficial effects of RYGB. Moreover, the persistent impairment of insulin and 
GLP-1-mediated endothelium-dependent relaxations suggest that the two hormones, which 
are partial agonists for the activation of endothelial NO release3, are a more sensitive tool 
compared to acetylcholine to investigate how metabolic modifications influence endothelial 
function3, 26.  
The endothelial Akt/eNOS pathway mediates GLP-1 receptor-dependent vascular effects 
and represents also the major signaling cascade activated by insulin. This pathway was 
rapidly up-regulated in aortae after RYGB as well as after liraglutide treatment in controls, 
but was blunted by administration of the antagonist exendin9-39 after RYGB.  
Further, the phosphorylation of JNK was reduced after RYGB and less potently so in 
control-liraglutide, but increased in RYGB-exendin9-39. JNK is a crucial mediator of insulin 
resistance in obesity29 and of endothelial dysfunction and oxidative stress23. Moreover, the 
inhibition of JNK signaling after administration of GLP-1 analogs protects endothelial cells 
against lipotoxicity-induced apoptosis and “eNOS uncoupling”24.  
Indeed, obesity-induced oxidative stress impairs NO bioavailability3; this was confirmed by 
the significant improvement of relaxations with the free radical scavenger PEG-SOD in sham 
operated rats, but not in RYGB or controls-liraglutide. Accordingly, NADPH oxidase activity 
and O2- concentration decreased rapidly after RYGB or in controls-liraglutide. As a consequence 
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of reduced aortic oxidative stress, “eNOS uncoupling”3, 24 which causes dysfunction of the 
enzyme, was prevented in RYGB as shown by higher dimerization and lower 
glutathionylation of eNOS. This explains the improved NO-dependent relaxations in RYGB 
compared to weight-matched or exendin9-39 treated RYGB rats. Like in RYGB, restored 
eNOS activity was paralleled by increased NO production after treatment with liraglutide. 
Hence, elevated GLP-1 levels and activation of GLP-1 receptor signaling play a key role in 
the improved endothelium-dependent vasodilatation after RYGB, independently of weight 
loss.  
 
Rapid improvement of endothelium-protective properties of HDL after RYGB involve a 
GLP-1-dependent mechanism 
 
Favorable lipid effects, i.e. higher HDL-C combined with lower LDL-C and TG levels, have 
been reported during long-term follow-up of patients after RYGB4, 11. The hormonal changes 
after RYGB are likely to influence lipid metabolism in addition to the weight loss per se, as 
suggested by the persistence of a beneficial lipid profile even in the fate of weight regain after 
surgery39. 
The present experiments demonstrate a specific effect of RYGB on HDL-mediated 
endothelial protection. HDL isolated after RYGB increased endothelial NO release, decreased 
endothelial apoptosis and expression of the adhesion molecule VCAM-1. Furthermore, the 
anti-oxidant activity of HDL and the capacity of the lipoprotein to stimulate cholesterol efflux 
from macrophages were also potentiated. All these protective effects did not improve in 
weight-matched rats, suggesting a weight-independent effect of RYGB. The most likely 
explanation for these weight–independent effects is the activation of the endothelial 
Akt/eNOS pathway after RYGB, which is the main pathway involved in the HDL-mediated 
NO release7, and its anti-apoptotic40, anti-oxidant7 and anti-inflammatory properties6, 8. 
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Likewise, HDL isolated from controls-liraglutide improved NO release, decreased endothelial 
apoptosis, oxidative stress and VCAM-1 expression similarly to that obtained from animals 
undergoing RYGB, suggesting a novel effect mediated by GLP-1. Hence, increased plasma 
levels of GLP-1 after RYGB exert protective endothelial effects via (1) improved HDL-
cholesterol properties; (2) direct activation of endothelial signaling pathways; and (3) insulin-
dependent vascular effects.  
 
Despite the effect of RYGB on the properties of HDL, no difference was observed in total 
cholesterol concentrations in rats after RYGB. However, the cholesterol distribution profile 
was changed towards smaller size HDL-cholesterol particles compared to sham-operated 
groups in which cholesterol eluted in larger particles (SOM Fig. 7), as described in animals 
fed high cholesterol41. These changes in cholesterol distribution profile may be linked directly 
to the improved properties of HDL after RYGB. 
GLP-1 analogs favorably modulate lipid metabolism in enterocytes and hepatocytes42. Here, 
liraglutide treatment resulted in smaller HDL-cholesterol particles, shifting the cholesterol 
distribution profile towards that seen after RYGB. Again, this effect does not seem to be 
mediated by the known GLP-1 receptor as shown by the lack of effect of exendin9-39.  
 
Translational relevance of the rapid improvement of endothelial protective properties of 
HDL after RYGB 
 
RYGB rapidly improved the endothelial protective properties of HDL in severely obese 
patients and thus conferred a translational relevance to the experimental animal data. Indeed, 
HDL isolated 14 days after RYGB improved endothelial NO release as a consequence of 
restored eNOS dimerization. Preserved NO bioavailability was paralleled by reduced 
endothelial NADPH oxidase activity, apoptosis and VCAM-1 expression, but also a higher 
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PON-1 activity and HDL-stimulated cholesterol efflux capacity. In a previous study, HDL 
isolated from obese adolescents one-year after RYGB did not improve pSer1177eNOS43. This 
result may be related to the fact that the assessment of eNOS activation was done by 
pSer1177eNOS alone; whereas NO release measurement combined to eNOS-dimerization, as 
performed here, may be more informative to assess disturbances of NO bioavailability3. 
Results obtained in the present study appear to be applicable to both genders, while previous 
reports involved mainly women5, 44. Furthermore, the properties of HDL improved 12 weeks 
after RYGB to the level of healthy subjects, although the patients were still obese. Moreover, 
HDL properties were impaired in BMI-matched patients. 
These observations suggest that the degree of weight and BMI loss induced by surgery is not 
sufficient or critical per se to improve the protective properties of HDL5, 44. Diet-induced 
weight loss is not associated with increased circulating GLP-1 and does not improve HDL 
properties 43, 45. In future studies, it will be relevant to evaluate the impact on endothelial 
protective HDL properties of the other two most commonly performed bariatric surgery 
procedures: vertical sleeve gastrectomy and gastric banding1. Sleeve gastrectomy produces 
enhanced GLP-1 secretion and improvements in T2DM, independently from weight loss 
similar to RYGB. On the other hand, adjustable gastric banding, which is a restrictive 
procedure, is associated with comparably smaller increases in circulating GLP-1 or in other 
gut hormones31. 
 
Finally, RYGB normalized the fasting plasma levels of bile acids in patients, expanding a 
previous observation regarding the restoration of the post-prandial rise in bile acids after 
RYGB46. Circulating bile acids which were also elevated in the rats after RYGB, interact with 
the endothelium and induce NO production via Akt/eNOS activation47; they reduce 
endothelial VCAM -1 expression47 and improve the ability of HDL to stimulate cholesterol 
efflux. Therefore bile acids may have contributed directly to the improved endothelial 
18 
CIRCULATIONAHA/2014/011791R1 
protective effects observed in the present study. However, since liraglutide treatment, in the 
absence of elevated bile acids levels, mimicked the beneficial metabolic effects of RYGB, 
GLP-1 signaling may be the dominating factor under the present experimental conditions. 
A major strength of the present study is its translational nature. It highlights with the animal 
experiments that the cardiovascular effects of RYGB likely derive from more than simple 
weight loss and that increased GLP-1 signaling may play a critical role for some surgery-
specific beneficial effects. The rapid improvement in the vascular protective properties of 
HDL applies also to morbidly obese patients undergoing RYGB.  
 
Conclusion 
The present study shows that RYGB exerts endothelium-protective effects beyond surgery-
induced weight loss. These effects are mediated, at least in part, by GLP-1 and GLP-1 
receptor signaling. These findings may allow the identification of less-invasive treatment 
strategies targeting molecular cardiovascular and metabolic pathways affected by obesity. 
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Figures legends 
 
Figure 1. 
Plasma levels of GLP-1 (A) and total bile acids (BA) (C) in RYGB compared to sham-
operated rats after surgery and after GLP-1 modulation for eight days (B) and (D). The 
elevated GLP-1 concentrations measured in sham control-liraglutide, probably reflected a cross-
reactivity of the assay with liraglutide. (*p<0.0001 RYGB vs. sham-operated rats; § RYGB 
and RYGB-exendin9-39 vs. controls and controls-liraglutide; ° controls vs. controls-liraglutide, 
p<0.002). Results are shown as mean ± SEM, n= 10-15 per group. 
 
Figure 2. 
A-B Relaxation of aortic rings isolated eight days after RYGB compared to sham-operated 
rats. Concentration–response curves during submaximal contraction to norepinephrine (NE) 
in response to insulin (A) and GLP-1 (B) (* sham-operated rats vs. RYGB; § controls vs. 
weight-matched, ° RYGB vs weight-matched, p < 0.05).  
C-D Effect of GLP-1 modulation for eight days on the relaxations to insulin (C) or GLP-1 
(D) (# RYGB vs. controls; ∼ RYGB vs. RYGB-exendin9-39; ° control-liraglutide vs. controls; 
*controls-liraglutide and RYGB vs. other study groups, p < 0.05), n= 6- 8 per group. 
 
Figure 3. 
GLP-1 receptor (GLP-1R) (A), pSer473-Akt (B) and p-JNK (C) protein expression from aortae 
isolated eight days after RYGB compared to sham-operated rats. eNOS protein Ser1177 (D) 
and Thr495 (E) phosphorylation and eNOS dimerization (F). Representative Western blots and 
densitometric quantification are shown. (G) Electron spin resonance spectroscopy analysis of 
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aortic NO production (* RYGB vs. other groups; § weight-matched vs. controls, p< 0.05), 
n=6-8 per group. 
 
Figure 4. 
(A) pSer473-Akt and p-JNK (B) protein expression from aortae isolated eight days after GLP-1 
modulation. eNOS protein Ser1177 (C), Thr495 (D) phosphorylation and eNOS dimerization 
(E). (F) Electron spin resonance spectroscopy analysis of aortic NO production (* RYGB vs. 
other groups; # controls-liraglutide vs. controls, § controls-liraglutide vs. RYGB-exendin9-39, p< 0.05), 
n=6-8 per group. 
 
Figure 5. 
Fluorescence detection of superoxide anions in rat aortae labeled with red-dihydroethidium 
(DHE) staining (A) and relative quantification (B). Nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase activity was measured in rat aortae (C) and in HAEC after 
stimulation with HDL(D) isolated from rats after RYGB and after GLP-1 modulation (* 
RYGB vs. controls; §RYGB-exendin9-39 vs. sham-operated rats, p≤ 0.05; # control-liraglutide vs. 
sham-operated rats, p< 0.05). (E) NADPH oxidase activity in HAEC stimulated with HDL 
isolated preoperatively (D0), at day 14 (D14), at 12 weeks (W12) post-RYGB and in BMI-
matched patients (*D0 vs W12; ç W12 vs BMI-matched, p< 0.05), n= 13 RYGB patients, 10 
healthy subjects and 9 BMI-matched patients. 
 
Figure 6. 
Endothelial NO production after HAEC stimulation with HDL isolated post RYGB (A) and 
after GLP-1 modulation (D). Endothelial anti-apoptotic effects (B) and endothelial anti-
inflammatory effect (C) of HDL after RYGB and after GLP-1 modulation (E, F, respectively) 
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(*RYGB vs. other groups; § controls vs. weight-matched; # controls vs. control-liraglutide;° 
controls vs. RYGB-exendin9-39, p<0.05), n=8-10 per group. SW indicates serum withdrawal. 
 
Figure 7. 
Endothelial NO production after HAEC stimulation with HDL isolated preoperatively (D0), at 
day 14 (D14) and 12 weeks (W12) post-RYGB, in BMI-matched patients and in healthy 
subjects, (n= 29 RYGB patients, 28 healthy subjects, 29 BMI-matched) (A). HDL-mediated 
eNOS activation measured by eNOS dimerization (n= 10 RYGB, 5 healthy, 6 BMI-matched) 
(B); endothelial anti-apoptotic effect (n= 29 RYGB, 28 healthy, 28 BMI-matched) (C); and 
anti-inflammatory effect of HDL on TNF-α–stimulated HAEC (n= 29 RYGB, 27 healthy, 29 
BMI-matched) (D). HDL associated PON-1 activity (n= 29 RYGB, 28 healthy, 28 BMI-
matched) (E) and HDL-stimulated macrophage cholesterol efflux (n= 28 RYGB, 28 healthy, 
29 BMI-matched) (F) (°D0 vs healthy; §D0 vs D14; *D0 vs W12; ΦD14 vs W12, #W12 vs 
healthy, ç W12 vs BMI-matched, p< 0.05). SW indicates serum withdrawal. 
 
Figure 8. 
Proposed cellular mechanisms involved in the beneficial effects of RYGB on endothelial 
function and HDL vaso-protective properties. The bioavailability of NO is decreased in 
obesity. Rapidly after RYGB, elevated GLP-1 levels through the activation of the GLP-1 
receptor activates the pSer473-Akt cascade enhancing peNOSer1177and eNOS dimerization 
while reducing peNOSThr495, JNK phosphorylation, NADPH oxidase activity and anion 
superoxide (O2-) production. This leads to higher NO levels and thus improved endothelial 
function. These effects are mimicked by liraglutide treatment of control rats and are blocked 
by exendin9-39 after RYGB. RYGB surgery and liraglutide improved also HDL-mediated NO 
production, endothelial anti-apoptotic, anti-oxidant and anti-inflammatory properties. The 
latter properties are independent of the activation of the known GLP-1 receptor and not 
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blocked by exendin9-39. HDL-associated PON-1 activity and cholesterol efflux improve after 
RYGB independently of GLP-1 modulation. 
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Supplementary Materials and Methods 
 
Animals and housing 
Adult male Wistar rats obtained from Janvier, France, weighted 250-300g at arrival. We 
performed a pilot experiment in order to define 1) the appropriate diet (high fat high 
cholesterol (HFHC) versus high fat (HF) only) to achieve diet-induced obesity (DIO) and 
impaired endothelial dysfunction; 2) the earliest time point for tissue harvesting and HDL 
isolation after RYGB in order to avoid the acute phase reaction post-surgical trauma and 3) 
the approximate amount of food eaten by the RYGB rats for weight matching of sham-
operated rats in the subsequent tests (see below). Seven weeks of HFHC diet induced 
endothelial dysfunction in contrast to HF diet alone (data not shown). The acute phase 
reaction after RYGB was resolved on post-operative day 8 (D8) as indicated by the time 
courses of Interleukin (IL)-1β, tumor necrosis factor (TNF)-α and IL-6 (data not shown). 
For all subsequent experiments, rats were transferred to a commercial HFHC containing 60% 
kcal fat and 1.25% cholesterol (Research Diets, New Brunswick NJ, USA) for a period of 7 
weeks prior to surgery; the same diet was offered post-surgery. Rats were initially housed 4 
per cage in Makrolon cages (Indulab, Gams, Switzerland). One week before surgery, they 
were single housed in wire mesh cages until the end of the experimental period. Rats were 
housed in a colony room with an average temperature of 23°C and a 12-hour light/dark cycle. 
The groups of animals used for the following two main experiments were: 1.) RYGB or 
sham-surgery fed ad libitum (controls) or weight- matched to RYGB and followed for a D8 
period (SOM Fig.1A); 2.) RYGB or controls followed for a D8 period and simultaneous in 
vivo GLP-1 intervention (SOM Fig.1B). Some parameters were also assessed in RYGB and 
sham-operated rats that were followed up for one month after surgery. The Cantonal Zurich 
Veterinary Office approved all animal experiments. 
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Surgeries 
Rats were randomly allocated to either RYGB or sham-operations. For the first experiment, 
24 rats with an average body weight of 590g underwent RYGB surgery, and 24 underwent 
sham-surgery, of which 12 with an average body weight of 592g were controls, and 12 with 
average body weight of 593g were weight-matched to RYGB. 
For the second experiment with simultaneous GLP-1 intervention, 22 rats with an average 
body weight of 502g underwent RYGB surgery and 12 rats with an average body weight of 
500g underwent sham-surgery.  
For the third experiment, 24 rats with an average body weight of 526g underwent RYGB 
surgery, and 24 rats underwent sham-surgery, of which 12 with an average body weight of 
531g were controls and 12 with an average body weight of 532g were weight-matched.  
Anesthesia was induced in a chamber filled with 5% isoflurane in room air (1 L/min). After 
an adequate depth of anesthesia was achieved, rats were shaved from sternum to pelvis 
followed by disinfection with Betadine scrub (Mundi Pharma, Basel, Switzerland). Rats were 
then placed in a supine position on a heating pad and positioned in a nose cone to maintain 
anesthesia (2%–3% isoflurane in room air, 0.8 L/min) for the duration of the surgery. All 
surgeries were conducted as previously described1. Briefly, a midline incision of 
approximately 4 cm starting just below the xiphoid process was performed. For the RYGB 
procedure, the proximal small bowel was transected approximately 20 cm distal to the pylorus 
of the stomach, creating a proximal and distal end of small bowel. The proximal end, being 
still continuous with the remaining portion of the stomach, constituted the biliopancreatic 
limb and was anastomosed to the distal small intestine, approximately 25–30 cm from the 
cecum, creating the common channel. For formation of the gastric pouch, the stomach was 
transected approximately 5 mm below the gastro-esophageal junction, creating a pouch of a 
size of less than 5% of original stomach size. The Roux-en-Y reconstruction was completed 
by connecting the distal end of the proximal small bowel to the gastric pouch, leading to 
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formation of the alimentary (Roux) limb. One single RYGB procedure lasted approximately 
100 minutes. For sham operations, an anterior gastrostomy with subsequent closure was 
performed. One single sham procedure lasted approximately 30 minutes. The abdominal wall 
and the skin were closed in layers after both operations. 
No RYGB rats died during surgery. Immediately following surgery, each rat received 5 mL of 
saline subcutaneously to compensate for fluid loss. Rats were then placed under indirect red 
light in a polycarbonate cage until they fully recovered from anesthesia, at which time they 
were returned to their home cages. Baytril 10mg/kg (Bayer, Germany) and Carprofen 5mg/kg 
(Norocarp, Norbrook Laboratories) were administered before surgery and for two days post-
surgery. Post-operatively, rats were fed HFHC diet and body weight and food intake were 
measured daily. Sham rats were randomly divided into controls or weight-matched rats; the 
latter were food-restricted (approximately 9-10 g/day based on the pilot experiment). Hence, 
the weight-matched group had a controlled food intake in order to match their weight to 
RYGB rats, this allowed the distinction between RYGB-specific from weight-dependent 
effects, since the only difference between these two study groups was RYGB surgery. During 
three-days post-operatively the HFHC solid diet was mixed with water to facilitate 
swallowing. 
 
In vivo GLP-1 interventions 
For the second experiment, sham-operated and RYGB rats were randomized to one of the 
following treatment groups, respectively: controls were treated with phosphate-buffered saline 
(PBS) (vehicle, n=6) or with liraglutide (controls-liraglutide; 0.2 mg/kg twice daily), n=6; RYGB 
were treated with vehicle (n=11) or RYGB exendin9-39 (10ug/kg/h), n=11. Liraglutide 
(Victoza; Novo Nordisk, Bagsvaerd, Denmark) or PBS vehicle were administered twice daily 
via subcutaneous (s.c.) injections for the eight-days follow-up period starting immediately 
post-surgery, with one injection in the light phase and one in the dark phase. The liraglutide 
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dose was increased stepwise over the first two treatment days (0.05 mg/kg, 0.1 mg/kg, 0.15 
mg/kg, 0.2 mg/kg) and then maintained at 0.2 mg/kg per injection. Exendin9-39 (Bachem, 
Bubendorf, Switzerland) or its vehicle was administered s.c. via osmotic minipumps (Alzet 
model 2001, Charles River, Germany) for the eight-days follow-up period. Implantation of the 
osmotic minipumps was performed immediately following the RYGB surgery while rats were 
still under anesthesia; minipumps were inserted via an incision made in the midscapular 
region. Dosages of liraglutide and exendin9-39 were selected based on previous in vivo 
results2-4.  
 
Rat blood collection 
Preoperative plasma was collected on the day of surgery in Microvette EDTA vacutainers 
(Sarstedt, Nümbrecht, Germany) supplemented with protease inhibitor cocktail (Sigma-
Aldrich, Saint Louis, Missouri,USA) and DPPIV inhibitor (Millipore, Darmstadt, Germany) 
and was kept on ice until centrifugation. Serum was collected in Microvette vacutainers 
(Sarstedt) and kept at room temperature until centrifugation. After centrifugation the 
supernatant was separated and stored at -80°C. Postoperative blood was collected at the time 
of euthanasia by heart puncture.  
 
Tissue harvesting 
Human insulin (10 mU/g; Humalog, Lilly, Indianapolis, Indiana, USA) or saline vehicle were 
injected intra-peritoneally for studying insulin signaling and action in subsequent ex vivo 
experiments as described5. Ten minutes after injection, rats were sacrificed and organs were 
harvested within 30 minutes; rats were anesthetized by isoflurane inhalation. The entire aorta 
from the heart to the iliac bifurcation was excised and placed immediately in cold modified 
Krebs-Ringer bicarbonate solution (pH 7.4, 37°C, 95% O2, 5% CO2) of the following 
composition (mmol/L): NaCl (118.6), KCl (4.7), CaCl2 (2.5), KH2PO4 (1.2), MgSO4 (1.2), 
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NaHCO3 (25.1), glucose (11.1), and calcium EDTA (0.026). The aorta was cleaned from 
adhering connective tissue under a dissection microscope and either snap-frozen in liquid 
nitrogen and stored at -80°C or used immediately for ex vivo organ chamber experiments. 
 
Organ chamber experiments  
For endothelial function experiments6, 2-3 mm long aortic rings were connected to an 
isometric force transducer (Multi-Myograph 610M, Danish Myo Technology A/S, Aarhus, 
Denmark), suspended in an organ chamber filled with 5 mL Krebs-Ringer bicarbonate 
solution (37°C, pH 7.4), and bubbled with 95% O2, 5% CO2 at 37°C. Isometric tension was 
recorded continuously. After a 30-minutes equilibration period, rings were gradually stretched 
to the optimal point of their length-tension curve as determined by the contraction in response 
to potassium chloride (100 mmol/L). Concentration-response curves were obtained in a 
cumulative fashion. Responses to acetylcholine (10-9 to 10-6 mol/L; Sigma-Aldrich), GLP-1(7–
36) amide (10-12-10-6mol/L; herein referred to as GLP-1; Bachem) and insulin (10-11 to 10-6 
mol/L; Humalog, Lilly) were recorded during submaximal contraction to norepinephrine (10-6 
mol/L, Sigma-Aldrich, USA) in the presence or absence of Nω-nitro-L-arginine methyl ester 
(L-NAME, 10-4 mol/L, Sigma-Aldrich), a non-selective nitric oxide (NO) synthase inhibitor 
or of the free radical scavenger polyethylene glycol–superoxide dismutase (SOD 150 U/mL, 
Sigma-Aldrich). The NO donor sodium nitroprusside (SNP, 10-10 to 10-5 mol/L; Sigma-
Aldrich) was added to test endothelium-independent relaxation. Relaxations were expressed 
as a percentage of the pre-contraction. In order to study the direct effects of GLP-1 on 
vascular function, cumulative concentration-relaxation responses were obtained for the 
peptide GLP-1 (7-36) amide (10-12 to 10-6 mol/L, Bachem) in the presence or absence of the 
highly specific GLP-1 receptor antagonist exendin9-39 (10-5mol/L 10 min before adding GLP-
1) (Bachem), L-NAME or PEG-SOD. 
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Western blotting 
Frozen aortae were pulverized and dissolved in lysis buffer (120 mmol/L sodium chloride, 50 
mmol/L Tris, 20 mmol/L sodium fluoride, 1 mmol/L benzamidine, 1 mmol/L dithiothreitol, 1 
mmol/L EDTA, 6 mmol/L EGTA, 15 mmol/L sodium pyrophosphate, 0.8 ug/mL leupeptin, 
30 mmol/L p-nitrophenyl phosphate, 0.1 mmol/L phenylmethylsulfonyl fluoride, and 1% NP-
40) for immunoblotting. The samples (30 ug) were subjected to SDS-PAGE gel for 
electrophoresis and incubated with SAPK/JNK and phospho-SAPK/JNK (Thr183/Tyr185) 
antibodies (Cell Signalling, Beverly, Massachusetts, USA), anti-eNOS/NOS Type III and 
anti-eNOS (pS1177) antibodies (BD Biosciences, San Jose, CA, USA), anti-eNOS (pT495) 
(BD Biosciences), Akt and phospho-Akt (Ser473) antibodies (Cell Signalling), anti-GLP-1-R 
antibody (Abcam, Cambridge, UK) and anti-GAPDH antibody (Millipore). The 
immunoreactive bands were detected by chemiluminescence (Amersham Biosciences, 
Buckinghamshire, UK) and quantified densitometrically with Image J software (National 
Institutes of Health, Bethesda, Maryland, USA). To assess eNOS dimer formation, non-
denaturing low-temperature SDS-PAGE was employed. Aortas were lysed as described above, 
treated with 6x Laemmli`s buffer not containing β-mercaptoethanol, and immediately 
subjected to 6% SDS-PAGE without prior incubation at 99°C.  
 
eNOS s-glutathionylation 
Twenty mg of aortic tissue were lysed in lysis buffer supplemented with 25mM N-
ethylmaleimide (NEM) (Sigma-Aldrich). eNOS was immunoprecipitated at 4°C overnight 
with NOS3 (C-20) agarose-conjugated antibody (Santa Cruz Biotechnology, Dallas, Texas, 
USA), eluted by two 10min 50°C 500rpm incubations with non-reducing 6xLaemmli`s buffer 
supplemented with 25mM NEM, and immediately subjected to non-reducing SDS-PAGE. S-
glutathione was detected using anti-glutathione antibody (Virogen, Watertown, MA, USA) 
supplemented with 2.5mM NEM, and anti-eNOS/NOS Type III antibody (BD Biosciences). 
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DHE staining on rats aortae 
Frozen 10 µm sections from aortae were cut with a Leica CM3050S cryostat and placed on 
positive-charged slides (Superfrost Plus, Thermo Scientific, Waltham, MA, USA). 
Dihydroethidium (Sigma Aldrich) was prepared as stock solution in DMSO, diluted in 
deoxygenated PBS (final concentration 5µM), and applied to frozen sections for 30 min at 
37°C. Nuclei were counterstained with Hoechst 33258 (Sigma Aldrich, final concentration 
1µg/ml). Slides were coverslipped and images taken on a SP8 microscope (10x/0.30 
objective; Leica, Solms, Germany), and quantified (ImageJ, NIH). DHE fluorescence was 
calculated by subtracting the autofluorescence signal (green channel) from the DHE signal 
(red channel), and normalized to the total fluorescent area. 
 
NADPH oxidase activity  
NADPH oxidase activity was measured using a commercial NADP/NADPH assay kit 
(Abcam) according to the manufacturer`s instructions. To measure the effect of HDL on 
endothelial NADPH oxidase activity, HAECs were treated with HDL (50ug/ml) for one hour 
at 37°C, as described7. 
 
Serum bile acid measurements 
Serum bile acids were measured with Cobas Integra 800 (Roche, Basel, Switzerland). 
 
Plasma insulin and GLP-1 measurements 
Customized rat and human duplex insulin/active GLP-1 Meso Scale Discovery 96-well plates 
were used to measure plasma insulin and GLP-1 concentrations, respectively, following the 
provided protocol (Meso Scale Discovery, Gaithersburg. MD, USA).  
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Serum HDL isolation by sequential density centrifugation 
HDL was isolated from fresh, fasting plasma by density gradient ultracentrifugation (HDL: 
density 1.063 to 1.21 g/cm3), as described8, 9. Potassium bromide (Merck KGaA, Darmstadt, 
Germany) was used to adjust the density. Purity of HDL was assessed by SDS-PAGE and 
subsequent Coomassie Blue staining of the gel. 
 
Cell culture 
Human aortic endothelial cells (HAEC) were obtained from (Lonza, Basel, Switzerland) and 
cultured in endothelial cell basal medium-2 (Lonza) supplemented with endothelial growth 
medium–SingleQuots as indicated by the manufacturer (37°C, 95% air / 5% CO2). HAECs 
were grown to sub-confluency and rendered quiescent before experiments by incubation in 
medium containing 0.5% fetal calf serum. For reverse cholesterol transport experiments, the 
murine macrophage cell line J774 was cultured on 75-cm2 flasks, in 10% FBS, 4.5g/l glucose 
RPMI medium 1640 (GIBCO, Life Technologies, Grand Island, NY, USA). 
 
TNF α- induced VCAM 1 expression in HAEC stimulated with HDL 
Expression of vascular cell adhesion molecule 1 (VCAM-1) was assessed in HAEC (passage 
7-9) stimulated with TNF-α on 96-well black-wall clear-bottom plates (BD). HAECs were 
rendered quiescent before experiments and treated overnight with or without HDL (10-μg 
protein/mL), followed by four hours of stimulation with TNF-α (100pg/ml) before fixation. 
Blocking with Licor buffer and incubating cells with VCAM 1 (R&D Systems, Minneapolis, 
MN, USA). Washing and adding secondary antibody, anti-goat 800CW (green) with Draq-5 
for normalization (680CW). For measurements the quantitative fluorescent imaging systems 
(LI-COR Odissey, Lincoln, Nebraska, USA) in channel 700CW and 800CW was used.  
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Measurement of endothelial cell NO production by 4,5-diaminofluorescein diacetate 
(DAF-2) staining.  
Endothelial cell NO production was determined as described10. In brief, after overnight 
starvation HAEC were incubated for one hour at 37°C with HDL (60 μg/ml) and DAF-2 
diacetate (1 μM; Cayman Chemical, Ann Arbor, Michigan, USA), that forms the fluorescent 
triazolofluorescein upon reaction with cellular NO. Following incubation, cells were 
transferred to a black microplate and fluorescence was measured on a Tecan Infinite M200 
PRO reader (Tecan, Maennedorf, Switzerland) with excitation and emission wavelenghts of 
485nm and 535nm, respectively.  
 
Measurement of aortic NO production.  
NO release in rat aortas was examined by electron spin resonance ESR spectroscopy analysis 
with the use of the spin-trap colloid Fe (DETC) 2 (Noxygen, Elzach, Germany), as described 
and validated previously11, 12. Briefly, Krebs-HEPES buffer (37°C), 500 μL of FeSO4 and 
DETC solution were added to each sample and incubated at 37°C for 60 minutes. Samples 
were frozen immediately in liquid nitrogen till recording with the use of NOX-E.5-ESR 
spectrometer (Bruker, Bremen, Germany). Signals were quantified by measuring the total 
amplitude after correction of baseline and subtraction of background signals. 
 
PON-1 activity 
Paraoxonase-1 (PON1) activity was determined using spectrophotometric measurement of 
rate of cleavage of phenylacetate (Sigma-Aldrich) to produce phenol in serum by monitoring 
the increase in absorbance at 270 nm at 25 °C, as described13. The resulting phenol 
concentration was calculated by the molar extinction coefficient, ε = 1,310 M–1 (pH 8.0). 
Each sample was run in duplicate. Activity of paraoxonase is expressed as umol/min/L.  
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In vitro apoptosis assay 
HDL anti-apoptotic properties were assessed in HAEC by evaluating cytoplasmic DNA-
histone complexes that increase after apoptosis associated DNA fragmentation, using the Cell 
Death Detection ELISAPlus kit (Roche Biochemicals) according to the manufacturer’s 
instructions. 
 
In vitro reverse cholesterol transport capacity of HDL 
J774 murine macrophages were seeded at a density of 1x106 /well in 24-well plates and the 
next day labeled with 2 µCi/mL 3H cholesterol for a minimum of 17 hours overnight in the 
presence of 2ug/ml acetyl-Coenzyme A acetyltransferase inhibitor (58-035, Sandoz 
Holzkirchen, Germany) in 500ul 0% FBS, 4.5g/l glucose RPMI 1640 medium (GIBCO, Life 
Technologies). The following day cells were washed 2x with PBS and equilibrated for six 
hours with 0.3mM 8-(4-bromophenylthio)-3’-5’-cyclic adenosine monophosphate (Sigma-
Aldrich) in the presence of acetyl-Coenzyme A acetyltransferase inhibitor in 500ul 0% FBS 
4.5g/l glucose RPMI medium. Apo B-depleted serum was obtained by polyethylene glycol 
precipitation, and 2.8% v/v Apo B-depleted serum was used as efflux acceptor for four hours 
in the presence of acetyl-Coenzyme A acetyltransferase inhibitor in 500ul 0% FBS MEM-
25mM HEPES medium. As controls, 2.8% v/v Apo B-depleted healthy human serum or 
MEM-HEPES medium alone were used. Supernatants were collected and centrifuged during 
five minutes at 12 000 rpm and 250ul were used for ten minutes of liquid scintillation 
measurements (PerkinElmer, Boston, MA;USA). Cells were washed 1x with PBS and 
intracellular cholesterol was extracted twice sequentially with 500ul 3:2 hexane:isopropanol 
for thirty minutes and fifteen minutes respectively, evaporated under a N2 flux and 
resuspended in 500ul isopropanol, from which 250ul were used for ten minutes liquid 
scintillation. Reverse cholesterol transport capacity of HDL was calculated as the ratio 
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between DPM counts of the supernatant vs. the intracellular 3H cholesterol scintillation 
measurements.  
 
Lipoprotein fractions 
To assess the distribution of cholesterol over the different lipoprotein fractions, lipoproteins 
were separated by size exclusion chromatography followed by online determination of lipids14 
or by fast protein liquid chromatography (FPLC) using two Superose-6 FPLC columns in 
series (HR10/30) in PBS with 0.1 mM EDTA, pH 7.5 at 0.5 ml/min. Columns were calibrated 
using high and low molecular weight standards (Pharmacia, Stockholm, Sweden). 500 ul of 
serum was loaded on the column, the first 10 ml were discarded and afterwards 70 samples of 
500 ul were collected for analysis. Cholesterol concentrations were measured using 
colorimetric and enzymatic methods with ready to use kits (Amplex red cholesterol kit, Life 
Technologies). 
 
Patient population  
Studies were performed according to the principles of the Declaration of Helsinki. The Local 
Research and Ethics committee approved the study (KEK-ZH-Nr. 2012-0260), and all 
patients gave written consent. The surgery group consisted of 29 patients undergoing primary 
laparoscopic proximal RYGB surgery. The RYGB procedure was performed as described15. 
All patients underwent a clinical, biochemical and pre-anesthetic evaluation, and all patients 
adhered to the study protocol and completed follow-up. Patients with unstable medical 
conditions such as recent coronary syndromes (within six months), congestive heart failure, 
systemic infection, acute illness, malignancy, or pregnancy, substance abuse, more than three 
alcoholic drinks per day, or psychiatric illness were excluded. Fasting blood samples were 
collected before (D0), at the first outpatient appointment two weeks (D14), and 12 weeks 
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(W12) post RYGB surgery. The BMI-matched group consisted of 29 obese patients, who 
were asymptomatic with no history of heart disease and not undergoing any cardiovascular 
conditioning program. 
The BMI, body weight, age and gender of these patients were matched to the BMI of patients 
12 weeks after RYGB. The control group consisted of 28 normal-weight volunteers matched 
for age and sex. They did not undergo any cardiovascular conditioning program. All control 
subjects were asymptomatic with no history of heart disease or accompanying disorders. 
 
Blood sampling 
Blood samples were obtained from fasting patients before RYGB (D0), in the morning of the 
first outpatient appointment two weeks after RYGB surgery (D14), and 12 weeks (W12) post 
RYGB surgery. Serum was collected in non-additive vacutainers, and plasma was collected in 
BD P800 vacutainers (containing DPPIV and protease inhibitors) that were kept at +4°C 
before and after blood collection. Blood samples were collected from fasting healthy subjects 
at the time of the study enrollment; plasma and serum were processed as described above. 
 
Statistical Analysis 
All analyses were performed with GraphPad Prism Software (version 5.0) or with SPSS 
software version 22.0 (Chicago, SPSS, Inc., Chicago, Illinois, USA). 
 
Supplementary Results 
 
RYGB reduces Food Intake and Body Weight compared to sham-operated controls 
In the first experiment, RYGB reduced food intake (FI) and body weight relative to sham-
operated ad libitum fed rats (controls) (SOM, Fig. 3 A-B). The body weight of the weight-
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matched group was well matched to RYGB rats, thus allowing the discrimination of surgery-
specific from weight-dependent effects since the only variable between these two study 
groups was the RYGB procedure. In the second experiment, FI and body weight were 
decreased to a similar extent in vehicle-treated RYGB versus sham-operated rats. Exendin9-39 
treatment in RYGB rat did not affect food intake or weight compared to the vehicle-treated 
RYGB (SOM, Fig. 3 C-D). Sham operated controls rats receiving liraglutide ate less initially, 
but they progressively increased their FI to a level similar to sham-operated controls on day 5 
after surgery. The initial weight decrease in liraglutide-treated sham-operated rats was similar 
to that in RYGB rats, but liraglutide-treated rats started to regain some weight three to four 
days after treatment onset, as described16 (SOM Fig.3 C-D). Some sham-operated and RYGB 
rats were followed up for one month in order to assess prolonged changes and compare 
weight-dependent effects (RYGB vs controls) with weight-independent effects (RYGB vs 
weight-matched). Sham-operated controls ate more compared to RYGB and weight-matched 
rats. The body weight of RYGB and weight-matched was well matched and remained stable 
around 470g after the initial weight loss (SOM Fig. 3 E-F).  
 
The improvement of vascular function after RYGB is weight-independent. 
Aortic contractions after norepinephrine (NE) were similar in sham-operated or RYGB rats 
(data not shown) in all experiments. Endothelium-independent relaxations in response to 
sodium nitroprusside (SNP) were equally preserved eight days after surgery (SOM Fig.4 C, 
H). Interestingly, one month after surgery, RYGB maintained a better relaxation in response 
to both insulin and GLP-1 with respect to sham-operated rats, whereas, acetylcholine-induced 
relaxation was restored in weight-matched equally to RYGB rats (SOM Fig. 4 D-F). Hence, 
although their weight was reduced as in the RYGB, weight-matched rats did not improve their 
relaxation upon stimulation with both hormones Because the response to acetylcholine one 
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month after surgery was similar in weight-matched and RYGB, insulin and GLP-1 are likely 
to be a more sensitive tools to investigate vascular function than muscarinic receptor-induced 
relaxation in this model of HFHC-induced obesity. After one month, endothelium-
independent relaxations to sodium nitroprusside (SNP) (10−10–10−5 mol/L) were similar in all 
groups (data not shown). 
 
Improved HDL profile after RYGB 
Despite similar  plasmatic HDL-cholesterol concentrations among the study groups (SOM Fig 
6 A), the analysis of the cholesterol distribution profile across all fast protein liquid 
chromatography (FPLC)-separated lipoprotein fractions revealed a clear shift towards smaller 
size and more uniformed HDL particle after RYGB (SOM Fig 6 B-C ). The cholesterol 
distribution profile attributed to the HDL particles in sham-operated rats was similar to what 
has been described in animals fed high cholesterol diets17. Notably, sham-operated controls 
treated with liraglutide exhibited cholesterol attributed to smaller HDL particles similar to 
RYGB, whereas the absence of effect after exendin9-39 compared to RYGB advocates an 
action independent of the classical GLP-1 receptor (SOM Fig.6 D). 
 
Patient characteristics and follow-up after RYGB  
The anthropometric characteristics, medications and lipid profile of obese patients undergoing 
RYGB surgery and those of the group BMI-matched to week 12 after RYGB are presented in 
SOM Table 1. All patients adhered to the study protocol and completed follow-up. The mean 
preoperative BMI was 45.44±1.0 kg/m2, n= six patients were super-obese (BMI> 50kg/m2). 
As expected, there was a high prevalence of obesity associated comorbidities at the time of 
study enrollment; T2DM was present in 20%; hypertension in 33% and obstructive sleep 
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apnea (OSAS) in 31% of the patients. There were five (17%) current smokers. At D14, the 
acute phase reaction post-surgical trauma was resolved as confirmed by the post-operative 
time course of IL-6, C-reactive protein (CRP) levels and leukocyte counting (data not shown); 
weight and BMI were reduced (42.20±1.0) (SOM Table 1), and decreased further at W12 
(weight loss= 18.2%; mean BMI 37.13 kg/m2). RYGB patient at baseline had significantly 
lower concentrations of HDL-C and higher concentrations of TG than controls. Postoperative 
changes of HDL-C followed a U shaped curve: there was a significant decrease from baseline 
to D14 followed by an increase at 12 weeks, but HDL-C was lower than in controls. 
Triglycerides levels improved by RYGB but remained higher than in controls, even 12 weeks 
after RYGB; these levels were lower 12 weeks after surgery than in the BMI-matched group. 
As expected, age-matched, healthy subjects significantly differed from obese with respect to 
weight and BMI. As shown in SOM Table 2, RYGB was associated with a significant 
increase in fasting circulating GLP-1 and bile acids levels paralleled by a significant decrease 
in glucose, insulin levels and in Homeostatic model assessment for insulin resistance 
(HOMA).  
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Supplementary Figure Legends 
Figure 1. 
Study design of the two main animal experiments (A) RYGB, sham-operated ad libitum fed 
(controls) or body weight- matched to RYGB rats followed up for eight days; (B) RYGB or 
sham-operated controls followed up for eight days with simultaneous in vivo pharmacological 
intervention. 
 
Figure 2. 
Plasma levels of GLP-1 (A) and total bile acids (B) in RYGB compared to sham-operated rats 
one month after surgery, (*RYGB vs controls and weight-matched, p=0.0001). Values are 
means ± SEM. n= 10-15 each group. 
 
Figure 3. 
A. Cumulative 24 hours-food intake in sham-operated controls (n=12), RYGB (n=17) and 
sham-operated weight-matched (n= 12) rats on the eight post-operative days. Average 
cumulative food intake was significantly higher in sham-operated controls vs. RYGB, and 
sham-operated weight-matched rats, (*** controls vs RYGB and weight-matched, p <0.001). 
No statistically significant difference was observed between RYGB and weight-matched rats. 
B.  Body weight before and eight days after surgery. Body weight was significantly 
higher in controls compared to RYGB rats starting from day 4; body weight did not differ 
between RYGB and weight-matched rats (*, **, *** controls vs RYGB; ° controls vs weight-
matched, p<0.05, p<0.01, p<0.001, respectively). C. Cumulative 24 hours-food intake in 
controls (n=6), controls-liraglutide (n=6); RYGB (n=11), RYGB-exendin9-39 (n=10). Average 
cumulative food intake was significantly higher in controls vs. RYGB and RYGB-exendin9-39 
rats (*, **, *** controls vs RYGB and RYGB-exendin9-39; °,°°,°°° controls vs controls-liraglutide, p 
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<0.05, p<0.01, p<0.001, resp.; § RYGB and RYGB-exendin9-39 vs. controls-liraglutide , p<0.05). 
There was no statistically significant difference between sham-operated controls and controls-
liraglutide after post-operative day 5. D. Body weight increased progressively in sham-operated 
controls with statistically significant differences with RYGB-exendin9-39 and RYGB (* controls 
vs RYGB and RYGB-exendin9-39; p<0.05). E. Cumulative 24 hours-food intake in controls 
(n=12), RYGB (n=19) and sham-operated weight-matched (n= 12) rats during the 1 month 
postoperative period. Average cumulative food intake was significantly higher in sham-
operated controls vs. RYGB, and weight-matched rats, (*** sham-operated controls vs RYGB 
and weight-matched, p <0.001). No statistically significant differences were observed 
between RYGB and weight-matched rats after surgery (°°RYGB vs weight-matched; p<0.01). 
F. Body weight after one month was significantly higher in controls rats compared to 
RYGB and sham-operated weight-matched (*** controls vs RYGB and weight-matched, p 
<0.001; °controls vs. RYGB, p<0.05). Results are presented as means ± SEM.  
 
Figure 4. 
A-C Endothelium-dependent relaxation (during submaximal contraction to norepinephrine 
(NE)) of aortic rings isolated eight days after RYGB compared to sham-operated rats (A) 
concentration-response curves in response to GLP-1 in the presence of the highly specific 
GLP-1 receptor antagonist exendin9-39 (10-5 mol/l, 10 min before GLP-1). (B) Line graphs 
show concentration-response curves to acetylcholine (Ach). (C) Endothelium-independent 
relaxation to the NO donor sodium nitroprusside (SNP) across the experimental groups 
(*sham-operated controls rats vs RYGB; ° sham-operated weight-matched vs. RYGB, 
p<0.05).  
D-F Endothelium-dependent relaxation one month after RYGB compared to sham-operated 
rats in response to insulin (D), GLP-1 (E) and (F) to acetylcholine (Ach) (*controls rats vs 
RYGB; ° weight-matched vs RYGB rats; § controls vs weight-matched, p<0.05 respectively). 
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G-H Effects of eight days treatment with liraglutide or exendin9-39 in sham-operated 
controls and RYGB, respectively, on endothelium-dependent (G) relaxation to Ach and 
endothelium-independent response to SNP (H) (*sham-operated controls vs RYGB, p<0.05). 
Results are presented as means ± SEM. n=6 to 8 per group. 
I-N Concentration-response curves in response to insulin and GLP-1 in the presence of the 
free radical scavenger polyethylene glycol–superoxide dismutase (SOD 150 U/mL) of aortic 
rings isolated eight days after RYGB and after GLP-1 modulation (* RYGB vs. sham-
operated weight-matched; # controls vs. controls-liraglutide; § controls vs. RYGB-exendin9-39, 
p<0.05). Results are presented as means ± SEM. n=6 to 8 per group. 
 
Figure 5. 
(A-B) GSH immunoblotting of eNOS immunoprecipitated from rat aortae eight days after 
RYGB and after GLP-1 modulation (* RYGB vs. sham-operated weight-matched;  p<0.01). 
 
Figure 6. 
HDL associated PON-1 activity. (A) Eight days after RYGB and after GLP-1 modulation (C). 
HDL-stimulated cholesterol efflux in J774 macrophages (as % of sham-operated controls); 
eight days after RYGB (B) and after GLP-1 modulation (D). (* RYGB vs. other groups; # 
sham-operated controls-liraglutide vs RYGB; ° sham-operated controls vs RYGB-exendin9-39, 
p<0.05). Results are presented as means ± SEM n=8-10 in each group. 
 
Figure 7. 
The abnormal HDL particles size induced by high fat high cholesterol diet is reversed after 
RYGB and liraglutide treatment. Total HDL-cholesterol levels eight days after RYGB were 
unchanged (A). Cholesterol distribution profile across all fast protein liquid chromatography 
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(FPLC)-separated lipoprotein fractions from samples isolated eight days (B) and one month 
after surgery (C) and after liraglutide or exendin9-39 treatment in sham-operated controls or 
RYGB rats, respectively (D). Results are presented as means ± SEM; n=5-7 per group. 
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Table 1: Clinical and Anthropometric Characteristics in Patients and Healthy Subjects  
Unless specified otherwise, values are means ± SE. Letters indicate statistically significant difference from : (a) Healthy, (b) D0, (c) 
D14, (d) 12W; (e) BMI-matched to 12W post RYGB; p<0.05.  
For Log LDL: b vs. c, p=0.001; b vs. e, p<0.0001; d vs. e, p=0.03.  
For HDL: p<0.0001 except for b vs. e, p=0.01 
For Log TG: p <0.0001 except for c vs. e, p=0.002; b vs. e, p=0.03 and d vs. e, p=0.003.  
 
BMI, body mass index. OSAS, obstructive sleep apnea syndrome. LDL, low density lipoprotein. HDL, high density lipoprotein. TG, 
triglycerides. ACEI, Angiotensin-converting-enzyme inhibitors. 
  RYGB 
                D0                                        D14                                    12W  
(n=29) 
BMI-matched to 12W 
RYGB 
(n=29) 
Healthy 
(n =28) 
Age, years 40.9 ± 1.7     42.72.1 37.82.4 
Female gender, n (%) 17 (58.6%)     19 (65%) 14 (50%) 
Height, m 1.7 ± 0.01     1.7± 0.01 1.7± 0.01 
Body weight, kg 134.0 ± 3.7a 124.0 ± 3.4ab 109.3 ± 3.4ac 110.3±3.8abc 66.0±1.8 
BMI (kg/m2) 45.4 ± 1.0a 42.2 ± 1.0ab 37.0 ± 1.0abc 37.15±0.9abc 21.9±0.3 
Current smokers (%) 5/29 (17%) 4/29 (14%) 3/29 (10%) 5/29 (17%)   
Diabetes, n (%) 6/29 (20.7%) 4/29 (13.8%) 0/29b (0%)b 2/29 (6.9%)   
OSAS 9/29 (31.0%)  7/29 (24.1%) 6/29 (20.7%)  10/29(34.5%)   
Lipid profile           
Total cholesterol (mmol/l) 4.8 ± 0.2 4.2 ± 0.2ab 4.0 ± 0.1ab 5.10± 0.20 4.89± 0.10 
Log LDL (mmol/l) 1.04 ± 0.05 0.89 ± 0.06b 0.85 ± 0.05b 1.06± 0.07bd 0.98± 0.06 
HDL (mmol/l) 0.97(0.82-1.21) 0.77 (0.67-0.97) 0.89 (0.82-1.02) 1.17 (1.01-1.46)ab 1.58 (1.29-1.88) 
LDL/HDL 3.14±0.23a 3.35±0.24a 2.70±0.16abc 2.65±0.19 1.87±0.19 
Log TG (mmol/l) 0.45±0.07a 0.53±0.06a 0.34±0.04 0.77±0.12abc 0.13±0.08 
Medications           
Metformin, n (%) 3/29 (10.3%) 2/29 (6.9%) 0/29 (0%)b 2/29 (6.9%)   
ACEI (%) 2/29 (6.9%) 2/29 (6.9%) 0/29 (0%) 1/29 (3.4%)   
Sartans 2/29 (6.9%) 2/29 (6.9%) 2/29 (6.9%) 0/29   
B-blockers 5/29 (17.2%) 5/29 (17.2%) 1/29 (3.4%)b 0/29   
Statins 0/29 (0%) 0/29 (0%) 0/29 (0%) 6/29 (20.7%)bcd   
Ca-channels blockers 2/29 (6.9%) 2/29 (6.9%) 1/29 (3.4%) 0/29   
Diuretics 3/29 (10.3%) 2/29 (6.9%) 1/29 (3.4%) 1/29 (3.4%)   
Others (Gliptins) 1/29 (3.4%) 1/29 (3.4%) 0/29 (0%) 0/29   
Table 2: GLP-1, bile acids and glycemic profile in Patients and Healthy Subjects  
GLP-1, Glucagon-like peptide-1. HOMA IR, Homeostatic model assessment for insulin resistance. 
  
RYGB  
D0                                            D14                              W12 
(n=29) 
BMI-matched 
to 12W 
RYGB 
(n=29) 
Healthy  
(n =28) 
Log GLP-1, pg/ml -0.76±0.2a 0.69±0.1b 0.40±0.1b   0.29±0.13 
Log Bile acids, umol/L 2.02±0.06a 2.19±0.05ab 2.39±0.06bc   2.4±0.06 
Glucose, mmol/L 6.40±0.25a 5.39±0.11b 5.12±0.11b 5.49±0.27 5.29±0.15 
Log Insulin, UI/ml 2.69±0.16a 2.49±0.09ab 2.28±0.1b 2.41±0.113ac 1.58±0.16 
Log HOMA IR 0.69±0.15a 0.48±0.09ab 0.20±0.11abc 0.37±0.13a -0.42±0.16 
Unless specified otherwise, values are means ± SE. Letters indicate statistically significant difference from : (a) Healthy, (b) D0, (c) 
D14, (d) 12W, (e) BMI-matched to 12W post RYGB; p<0.05.  
For Log GLP-1: p<0.0001. 
For Log Bile acids: p <0.0001; except c vs. d, p< 0.01.  
For Glucose: b vs. d 0.002 
For Log Insulin: p<0.0001; except: c vs. d, p< 0.03; a vs. e, p< 0.001 
Log HOMA IR: p<0.0001; except: b vs. d, p< 0.01; c vs. d, p< 0.004; a vs. d 0.004. 
Table 3.  Overwiev of the RYGB-specific, weight-independent and GLP-1-mediated rapid effects on endothelial–mediated 
relaxation and HDL vaso-protective properties 
*weight-independent effects are considered effects observed in RYGB but not in sham-operated weight-matched rats. 
†Improved by liraglutide suggests effects involving GLP-1 activated signaling.  
‡ Blocked by exendin9-39 suggests effects mediated by the classical GLP-1 receptor. 
§ protective HDL properties observed in patients 12 weeks after RYGB but not in the BMI-matched patients. 
  Rats eight days after RYGB  
  
Patients after 
RYGB  
  
  Improved after RYGB 
and weight-
independent* 
Improved by 
 liraglutide in   
sham-operated 
controls† 
Blocked by 
exendin9-39 in 
RYGB‡ 
  
Vasorelaxation in response to:         
  
Insulin 
  
YES 
 
YES 
 
YES 
  
  
  
GLP-1 
  
YES 
  
YES 
  
YES 
  
  
Acetylcholine 
  
YES 
  
YES 
    
          
HDL- mediated vaso-protective 
properties: 
        
NO production YES YES   YES § 
Anti-apoptosis YES YES   YES 
Anti-inflammatory YES YES   YES § 
Anti-oxidant 
(NADPH oxidase activity) 
YES YES YES § 
PON-1 activity YES     YES § 
Cholesterol efflux YES     YES § 
